Proyecto
 (2020)

A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants

Más información

Fecha de publicación: 2020
Objetivos: Primary Outcome Measures: 1) Percentage of participants with HIV-1 RNA <50 copies/mL. 2) Percentage of participants experiencing ≥1 adverse events (AEs). 3) Percentage of participants discontinuing from study treatment due to AE(s).
Año de Inicio/Término: 2020-2025
Financiamiento/Sponsor: Merck Sharp & Dohme LLC
Rol del Usuario: COINVESTIGADOR(A)
URL: https://clinicaltrials.gov/ct2/show/NCT04233879
DOI:

MK-8591A-020